[Human Resources Development in Cancer Research].

There exist many issues concerning human resources development in cancer research. Not a single solution does not work, but correlative issues should be continuously and comprehensively considered. Board certification platform, timing of decisions to go to graduate school of medicine and to study abroad for young researchers: leading to the education for physician scientists, grants(Kakenhi)reduction, the Work System Reform for medical doctors, promotion women researchers for managerial posts, etc.

A Phase II Trial of Trifluridine/Tipiracil in Combination with Cetuximab Rechallenge in Patients with RAS Wild-Type mCRC Refractory to Prior Anti-EGFR Antibodies: WJOG8916G Trial.

Background: Trifluridine/tipiracil (FTD/TPI) improved the overall survival in patients with metastatic colorectal cancer (mCRC) who had previously received standard chemotherapies; however, the clinical outcomes remain poor.

Objective: A multicenter phase II study aimed to assess the efficacy and safety of FTD/TPI plus cetuximab rechallenge.

Patients And Methods: Patients with histologically confirmed RAS wild-type mCRC refractory to prior anti-epidermal growth factor receptor (anti-EGFR) antibody were enrolled and treated with FTD/TPI (35 mg/m twice daily on days 1-5 and 8-12) plus cetuximab (initially 400 mg/m, followed by weekly 250 mg/m) every 4 weeks.

Genomic Landscape of Primary Tumor Site and Clinical Outcome for Patients with Metastatic Colorectal Cancer Receiving Standard-of-Care Chemotherapy.

Background: Primary tumor site and genomic status are utilized for regimen selection in metastatic colorectal cancer; however, the impact on clinical practice is not well known.

Objective: We aimed to clarify the impact of primary tumor site and genomic status on clinical practice in metastatic colorectal cancer.

Methods: The relationship between primary tumor site, genomic alterations, and clinical outcomes was evaluated in patients with untreated metastatic colorectal cancer using real-world data of a prospective observational study, SCRUM-Japan GI-SCREEN with clinical and genomic data set in 1011 patients enrolled from February 2015 to March 2017.

Rationale and design of the TRUSTY study: a randomised, multicentre, open-label phase II/III study of trifluridine/tipiracil plus bevacizumab versus irinotecan, fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following first-line oxaliplatin-based chemotherapy.

Background: Trifluridine/tipiracil is an oral agent approved for the treatment of patients with metastatic colorectal cancer (mCRC). Trifluridine is an antineoplastic thymidine analogue, and tipiracil improves its bioavailability. A phase I/II C-TASK FORCE study of trifluridine/tipiracil plus bevacizumab for patients with refractory mCRC demonstrated promising efficacy results with mild toxicity profile.